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Creatine (Cr) and its analogue, 2-imino-1-imidazolidineacetic acid
or cyclocreatine (cyCr), have both been demonstrated to have anti-
tumour effect in vivo in some, but not all, transplanted human and
rodent tumours (Lillie et al, 1993; Miller et al, 1993). Cyclocreatine
also has an anti-tumour effect in vitro (Martin et al, 1994a,  b;
Schiffenbauer et al, 1995, 1996; Bergnes et al, 1996) and has been
shown to induce intracellular water accumulation (Schiffenbauer et
al, 1995). Furthermore, cyCr inhibits tumour cell proliferation in all
phases of the cell cycle (Martin et al, 1994b) and induces stabiliza-
tion of microtubules (Martin et al, 1995). The phosphorylation of
cyCr by creatine kinase (CK) (Cr + MgATP ® PCr + MgADP +
H+) seems to be crucial for the anti-tumour effect because (1) the
growth-inhibitory effect of cyCr is dependent on in vitro CK
activity and (2) transfection of the creatine kinase gene into cells
with low CK activity increases the in vitro growth-inhibitory effect
of cyCr significantly (Lillie et al, 1993). In a recently published
study of two different tumour cell lines, cellular swelling and phos-
phocyclocreatine (PcyCr) accumulation was observed only in the
cell line with the highest creatine kinase activity, in spite of growth
inhibition of both cell lines (Schiffenbauer et al, 1996).
CK activity has been associated with tumour growth in several
studies, but a direct relationship has not been derived. CK is
overexpressed in most tumours compared with their non-malig-
nant tissues of origin (Shatton et al, 1979), and growth inhibition
of breast cancer tumours by oestrogen withdrawal was shown to
down-regulate creatine kinase activity (Kristensen et al, 1995).
Elevated plasma creatine kinase activity is a poor prognostic factor
in several cancers, e.g. small-cell lung cancer (Carney et al, 1984),
possibly as a result of leakage of enzymes from tumour tissue to
plasma after, for example, myocardial infarcts. Despite the lack of
sufficient information on the nature and intracellular localization
of the CK isoenzymes in different tumours, it is apparent that the
isoforms have distinct roles in neoplastic tissues. Plasma levels of
the cytosolic brain isoenzyme (CK-B) were found to correlate with
the aggressiveness of the neoplastic clone (Neri et al, 1985). The
oncogenic activity of adenovirus E1a was accompanied by induc-
tion of CK-B expression (Kaddurah-Daouk et al, 1990), while the
tumour-suppressor activity of p53 was associated with a positive
regulation of the cytosolic muscle isoenzyme (CK-M) and a nega-
tive regulation of CK-B (Zhao et al, 1994).
CK isoenzymes have also been associated with tissue growth
and development in non-malignant tissues. During developmental
stages, fetal tissues express mainly CK-B (Hall and DeLuca,
1976). The mitochondrial isoenzyme (CK-mit) is expressed during
the post-natal period (McAuliffe et al, 1989) and is associated with
the development of the oxidative capacity of the tissue (Perry et al,
1988; Walliman et al, 1992). Recently, it has been demonstrated
that the specific CK isoform expression may be crucial in
achieving selective inhibitory effects of Cr and cyCr on liver
regeneration (Askenasy and Koretsky, 1997).
The aim of the present study was to determine the growth-
inhibitory effects of Cr and cyCr on LS174T human colon
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Summary Creatine (Cr) and cyclocreatine (cyCr) have been shown to inhibit the growth of a variety of human and murine tumours. The
purpose of this study was to evaluate the anti-tumour effect of these molecules in relation to drug accumulation, energy metabolism, tumour
water accumulation and toxicity. Nude mice carrying a human colon adenocarcinoma (LS174T) with a creatine kinase (CK) activity of 2.12
units mg–1 protein were fed Cr (2.5% or 5%) or cyCr (0.025%, 0.1% or 0.5%) for 2 weeks and compared with controls fed standard diet. Cr
concentrations of 2.5% and 5% significantly inhibited tumour growth, as did 0.1% and 0.5% cyCr. In vivo 31P magnetic resonance
spectroscopy (MRS) after 2 weeks of treatment showed an increase in [phosphocreatine (PCr)+phosphocyclocreatine (PcyCr)]/nucleoside
triphosphate (NTP) with increasing concentrations of dietary Cr and cyCr, without changes in absolute NTP contents. The antiproliferative
effect of the substrates of CK was not related to energy deficiency but was associated with acidosis. Intratumoral substrate concentrations
(measured by 1H-MRS) of 4.8 mmol g–1 wet weight Cr (mice fed 2.5% Cr) and 6.2 mmol g–1 cyCr (mice fed 0.1% cyCr) induced a similar
decrease in growth rate, indicating that both substrates were equally potent in tumour growth inhibition. The best correlant of growth inhibition
was the total Cr or (cyCr+Cr) concentrations in the tissue. In vivo, these agents did not induce excessive water accumulation and had no
systemic effects on the mice (weight loss, hypoglycaemia) that may have caused growth inhibition.
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Denmarkadenocarcinoma implanted subdermally in nude mice. This
tumour line has previously been used for extensive studies of
tumour physiology and drug therapy, it has a relatively high CK
activity and it is growth inhibited by Cr and cyCr. In view of the
mechanisms presumed to contribute to the growth-inhibitory
effects of these agents, we have evaluated: (1) intratumoral accu-
mulation of Cr and cyCr delivered orally; (2) concentrations of the
phosphorylated products of the CK substrates (PCr and PcyCr) and
energy metabolic state of the tumours determined by in vivo 31P-
MRS; (3) tumour water content and (4) systemic toxicity of these
agents during a 2-week feeding period. These data were analysed
with reference to CK activity and the isoenzyme distribution in the
tumour.
MATERIALS AND METHODS
Animals and tumour lines
LS174T is a human colon adenocarcinoma cell line (ATCC,
Rockville, MD, USA) maintained in our lab as a cell culture and
serially passed in nude mice. Six- to eight-week-old males of
nu/Sed origin were anaesthetized with ketamine (Ketalar, Parke-
Davis, Morris Plains, NJ, USA) 100mg kg–1 body weight, and
xylazine (Rompun, Miles Inc, Shawnee Mission, KA, USA)
10mg kg–1 body weight, and 1-mm3 LS174T tumour chunks were
implanted subcutaneously in the right hind leg. Institutional guide-
lines for animal welfare and experimental conduct were followed.
Experimental set-up
When the tumours became visible, the mice were split into a
control group and six experimental groups; controls were fed stan-
dard liquid rat diet (LiquiDiet ‘82, Bioserv, Frenchtown, NJ, USA)
from special glass liquid diet dispensers. The experimental groups
were fed the same liquid diet mixed with different concentrations
of Cr (Sigma Chemical, St Louis, MO, USA) and cyCr (Aldrich
Chemical, Milwaukee, WI, USA) as follows: 2.5% Cr, 5% Cr,
0.025% cyCr, 0.1% cyCr, 0.5% cyCr and 1% cyCr (all concentra-
tions are w/v). Diet and water were given ad libitum. For 2 weeks
the tumours were measured bidimensionally three times weekly.
The animals were weighed before and during the feeding, and the
volume of diet consumed was read from the diet dispenser. At the
end of the 2-week feeding period the animals were anaesthetized
with ketamine/xylazine and in vivo 31P-MRS was performed. After
spectroscopy, blood samples were taken for determination of
serum glucose; tumour and liver samples were taken for determi-
nation of total concentrations of CK substrates (Cr + cyCr), lactate
and alanine, wet weight–dry weight ratios and CK activity.
Tumour growth was measured in a similar set-up during treat-
ment of each mouse with i.p. injections of 10mg cyCr in 0.3ml of
saline daily and compared with growth of control tumours given
i.p. saline injections. cyCr was dissolved in hot saline (60–70°C)
in a water bath and cooled to 37°C before injection.
Tumour growth curves
Mean tumour growth curves were constructed according to a trans-
formed Gompertz function, as described by Spang-Thomsen et al
(1980). For determination of the a-value, a simple transformation
of the Gompertz function was used:
Transformed tumour size = ln [ln A(max) – ln A(t)] = ln b/a – at
where a and b are constants, A(max) is the theoretical maximum size
and A(t) is the tumour size at time t. This growth function depicts a
straight line with negative slope (–a) when the transformed tumour
size is plotted against time. ln A(max) was set to 7, corresponding to
tumour dimensions of approximately 15 ´15mm2. Consequently, all
variation in growth is placed in one single parameter, a, that
expresses the growth of the individual tumour.
31P-MRS
Spectra were collected with a 300-MHz Bruker Biospec spectro-
meter (horizontal wide bore) operating at 121.5MHz for 31P. An 8-
mm, two-turn surface coil was located above the tumour. Spectra
were collections of 256 transients of 60°pulses at a repetition time
of 1s. Fully relaxed spectra were recorded at a repetition time of
10s for calculation of the saturation factors for each individual
phosphorus resonance (n= 10). Free induction decays were multi-
plied with a Lorentzian window of 30Hz. Peak areas were
integrated with a Bruker software subroutine, after baseline
correction. Phosphorus metabolites were quantified against an
external reference containing 8mmol of methylphosphonic acid
(MPA) and 20mmol of gadolinium diethylenetriaminopentacetic
acid (gadolinium DTPA). Data are reported as mmol coil–1 because
the volume detected by the coil was not quantitated.
Saturation transfer experiments were performed to evaluate
magnetization transfer from PCr to nucleoside triphosphate (NTP)
(forward CK direction). 31P spectra were collections of 20 tran-
sients (90°pulses) with repetition times of 10s. Magnetization
transfer was measured using a narrow-band, low-power radiofre-
quency (RF) pulse with increasing durations (0.5, 1, 3, 5, 7 and
9s). The saturating pulse was applied for each duration at the reso-
nance frequency of g-NTP (Mz) and at a symmetrical location
downfield from the PCr peak (Mo). The apparent longitudinal
relaxation time (Tlapp) was determined from the mono-exponential
decay of Mz/Mo (a pair of saturated/control spectra). Pseudo-
first order rate constants (k) were calculated according to k=
(1 – Mss/Mo/Tlapp, where Mss is the steady-state value of Mz. The
reaction velocity was calculated from the rate constant and the
concentration of PCr (per surface coil detection volume).
1 H-MRS
1H-MRS was performed on perchloric acid extracts of tumour and
liver tissue samples. Spectra were collected with a 300-MHz
Bruker spectrometer (vertical narrow bore). Fully relaxed spectra
were collections of eight transients of 90°pulses with a relaxation
delay of 8s. After baseline correction, peak areas were integrated
with a Bruker software subroutine. Proton resonances were
assigned against 1mmol of trimethylsylilpropionic acid (TSP),
which was also used to quantify the metabolites.
Perchloric acid extracts
Tissue samples were diluted with 5 volumes of 5% perchloric acid,
homogenized and centrifuged at 15000gfor 15min at 4°C. The
supernatant was neutralized with potassium hydroxide and
centrifuged again at 20000gfor 20min at 4°C. The supernatant
was lyophilized and stored at –85°C. Extract powder was diluted
in 0.6ml of D2O in the presence of 1mMethyleneglycol (bis-
aminoethyl ether)tetraacetic acid (EGTA) and 1mMTSP.
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CK activity
Tissue samples were homogenized in 99 parts of the following
buffer: 26 mM Tris, 0.3 M sucrose, 20 mM b-mercaptoethanol and
1%  tert.-octylphenoxy-poly(oxyethylene)ethanol (Sigma). CK
activity was determined in the direction of Cr to PCr at 37°C by
the spectrophotometric assay described previously (Kristensen et
al, 1995) and in the opposite direction at 37°C by a commercially
available kit (cat. no. 45-1, Sigma).
Gel electrophoresis
CK distribution was tested in samples of tissue homogenate at a
final dilution of 1:200. One-microlitre volumes were applied to a
1% agarose Multitrac CK electrophoretic isoenzyme gel (Ciba-
Corning, Marshfield, MA, USA) which uses a hexokinase/glucose
6-phosphate dehydrogenase coupled enzyme system.
Serum glucose
Serum glucose was determined spectrophotometrically using a
commercially available kit (Sigma Diagnostics, St Louis, MO,
USA, cat. no. 510-A).
Tissue water content
Tissue samples were blotted and weighed (ww), and stored for
24 h at 85°C for determination of the dry weight (dw). Total tissue
water content was calculated according to (ww–dw) dw–1, and is
expressed in units of ml g–1 dw.
Statistics
Data from each experimental group were compared with data from
the control group by a t-test (SPSS statistics).
RESULTS
Tumour growth
The growth of control tumours and tumours treated with different
doses of Cr and cyCr is shown in Figure 1. Both 2.5% and 5% Cr
induced significant growth inhibition (P < 0.05) (Figure 1A),
whereas the growth inhibition induced by the lowest dose of cyCr,
0.025%, was non-significant. Tumour growth was significantly
inhibited by 0.1% and 0.5% cyCr (P < 0.05) (Figure 1B). Figure 2
shows the growth curve of tumours treated with i.p. injections of
cyCr (10 mg daily) as compared with controls. Also i.p. injections
of cyCr induced significant growth inhibition (P < 0.05).
Toxicity
The animals in all five experimental groups fed Cr or cyCr lost
significant amounts of weight during the feeding period compared
with controls, and the weight loss was correlated to the mean
amount of liquid diet intake (r2 = 0.82). There was not, however,
any correlation between weight loss and tumour growth inhibition
measured as the a-value for each individual tumour (r2 = 0.16).
The mice fed 0.5% cyCr lost weight rapidly, probably because of
the very limited diet intake, and all animals were sacrificed on day
20 because of severe (>30%) weight loss.
Mean serum glucose level after 2 weeks of feeding was 11.5 mM
(range 3.2–24.9 mM) in the control group, 11.3 mM (range 6.5–
16.2 mM) in the 2.5% Cr group, 14.2 mM (range 11.2–18.2 mM) in
the 5% Cr group, 20.1 mM(range 13.2–23.2 mM) in the 0.025% cyCr
group and 12.8 mM (range 9.2–15.2 mM) in the 0.1% cyCr group.
There was no significant decrease in mean serum glucose concentra-
tion in any of the experimental groups compared with controls.
Intraperitoneal injections of cyCr were given in a dose calcu-
lated to correspond to the ingested dose of mice fed 0.1% cyCr
(10 mg daily i.p.). This dose did not induce significant weight loss
or other signs of toxicity when given intraperitoneally.
31P- and 1H-MRS
Typical in vivo 31P- and extract 1H-MR spectra are shown in Figure
3. Uptake of the substrates by the tumour was evident from the
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Figure 1 Inhibitory effect of Cr (A) and cyCr (B) on growth of LS174T
human colon adenocarcinomas. Cr in doses of 2.5% (l l, n = 7) and 5% (n,
n = 8) and cyclocreatine in doses of 0.025% (n n, n = 8), 0.1% (s, n = 6) and
0.5% (s s, n = 4) were given in liquid diet from day 10 (arrow) after
subcutaneous tumour implantation. The a-values for each experimental
group were compared with those of control tumours (l, n = 7) by a t-test.
*P < 0.05. †All animals sacrificed on day 20 as a result of severe weight loss
Figure 2 Tumour growth-inhibitory effect of cyclocreatine 10 mg i.p. daily
(s, n = 9) compared with controls (l, n = 9). Treatment was initiated on
day 6. *P < 0.05
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increase in PCr and PcyCr contents. The absolute levels of NTP
and Pi were not significantly different after 2 weeks of feeding
with CK substrates, with the exception of the Cr 5% group. At this
dietary concentration, Pi concentrations were lower (P < 0.05).
None of the experimental groups experienced a decrease in
NTP/Pi, and reduction of Pi caused a significant increase in this
index only in mice fed with Cr 5% (P < 0.05). It can be seen from
Table 1 that the PCr/Pi ratio increased in the Cr 5% group (P <
0.01) and the PcyCr/Pi ratio increased in both groups fed with cyCr
(P < 0.05). Acidic intracellular pH values were observed in all of
the experimental groups, as compared with controls (P < 0.002
and P < 0.02 with Cr and cyCr feeding respectively).
Total PCr+Cr and PcyCr+cyCr contents in the tumours
increased as a function of the dietary concentration (Table 1). In
Cr-fed animals, intratumoral concentrations increased 2.5- and 5-
fold at dietary concentrations of 2.5% and 5% Cr. Table 1 shows
the levels of PCr and PcyCr detected in different tumours. It was
not possible to distinguish PCr from PcyCr in the MR spectrum.
The total increase in PCr+Cr was markedly larger than the
increase in PCr concentrations. A similar disproportional increase
in total vs phosphorylated substrates was observed in tumours of
cyCr-fed animals.
There was a strong correlation between Cr+cyCr concentration
and degree of growth inhibition (a-value) (r = 0.64, P = 0.002),
whereas no correlation was found between growth inhibition and
the concentration of phosphorylated compounds (r = 0.25, P =
0.29) (Figure 4).
Measurements of the magnetization transfer PCr to ATP are
presented in Table 2. The reaction velocity was slightly decreased
by Cr feeding (not significant). At the higher dose of cyCr, no
exchange was detected, indicating that the major fraction of the 31P
resonance was composed of PcyCr. At the lower cyCr dietary
concentration, the rate constant of saturation transfer was
markedly increased (P < 0.01 vs control), indicating the presence
of PCr in these tumours. As the relative concentrations of PCr and
PcyCr in these tumours were not known, the reaction velocity
could not be estimated.
Mean steady-state lactate and alanine concentrations measured by
1H-MRS were 24.1 mmol g–1 ww and 2.4 mmol g–1 ww, respectively,
Table 1 Metabolite concentrations, pH values and energy indices
Cr cyCr PCr+PcyCr NTP pH Pxx/NTP Pxx/Pi NTP/Pi
(mmol g–1 ww) (mmol g–1 ww) (mmol coil–1)( mmol coil–1)
Control 2.0 ± 0.5 – 7.66 ± 1.38 4.96 ± 1.04 7.37 ± 0.07 1.8 ± 0.3 2.6 ± 0.7 1.4 ± 0.3
Cr 2.5% 4.8 ± 1.6a – 6.64 ± 1.92 3.44 ± 0.96 6.94 ± 0.12a 2.2 ± 0.4 2.8 ± 0.7 1.3 ± 0.4
Cr 5% 10.3 ± 2.4a – 10.24 ± 1.6a 4.24 ± 0.88 6.99 ± 0.12a 2.8 ± 0.1a 6.1 ± 1.1a 2.2 ± 0.3a
cyCr 0.025% 3.2 ± 0.9 1.2 ± 0.2a 6.4 ± 1.60 3.6 ± 0.96 7.07 ± 0.10a 2.2 ± 0.2 3.5 ± 0.3a 1.6 ± 0.1
cyCr 0.1% 1.8 ± 0.4 6.2 ± 0.1a 9.04 ± 2.32 3.92 ± 0.96 7.00 ± 0.05a 2.6 ± 0.4a 4.3 ± 0.3a 1.7 ± 0.3
Values are given as means ± s.d. Pxx represents PCr and/or PcyCr. aP < 0.05 vs control.
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Figure 3 Representative in vivo 31P-MR spectrum of a LS174T tumour from
a mouse fed with 5% Cr (A). 1H-MR spectrum of tumour extract (B)
Figure 4 Relationship between Cr+cyCr (n) and PCr + PcyCr (l l)
concentration and growth inhibition (a-value). Cr+cyCr was correlated to a
(r = 0.64, P = 0.002). There was no significant correlation between
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in control tumours. Mean levels of lactate and alanine in the experi-
mental groups did not differ significantly from controls (data not
shown).
CK activity
Total CK activity (PCr ®Cr) in the tumours was 2.12 ±0.23mmol
(mg protein)–1 min–1 and 270 ±34mmol g–1 ww min–1. Gel elec-
trophoresis showed that 85 ±5% of the activity was attributable to
the BB dimer and 10 ±3% to the MB dimer. The MM band was
barely detectable. The presence of CK-mit was also apparent on
concentrated gels but its partial activity was too low to be quanti-
fied. No significant changes in total CK activity and isoenzyme
distribution were observed after feeding with Cr or cyCr.
Tumour and hepatic water content
Total tumour water contents and liver water contents are presented
in Figure 5. There was no significant difference in total water
contents when tumours from Cr- and cyCr-fed mice were
compared with controls. However, the total liver water contents
were significantly higher than control values in all experimental
groups.
DISCUSSION
The data presented demonstrate a significant inhibitory effect of
creatine and cyclocreatine on a human colon adenocarcinoma cell
line implanted in nude mice. Growth inhibition was best correlated
with intratumoral CK substrate concentrations, and was achieved
at dietary Cr and cyCr doses as low as 2.5% and 0.1%, respec-
tively, or daily doses of 10mg cyCr i.p. In vivo, these agents did
not decrease NTP/Pi and did not cause excessive intratumoral
water accumulation, as previously proposed for other cell lines in
vitro. We propose that phosphorylation of Cr and cyCr by CK
increases the intracellular accumulation of substrates, thus
indirectly increasing their anti-tumoral effect.
Energetic considerations
After 2 weeks of oral feeding with Cr or cyCr, the tumours showed
no signs of energy deprivation measured as PCr+PcyCr/NTP and
NTP/Pi. Cr and cyCr feeding increased the concentrations of the
phosphorylated CK substrate, without significant changes in NTP
and Pi levels. It is evident that the increase in PCr+PcyCr/NTP was
caused by enrichment of the tumours with CK substrates (Table 1).
The phosphorylation potential ([ATP][ADP]–1 [Pi]–1) is important
for regulation of oxidative metabolism and can be altered by
changes in the relative concentrations of substrates and products in
the CK equilibrium. At equilibrium, changes in the concentrations
of Cr or cyCr and PCr or PcyCr will influence the concentrations
of ATP, ADP and H+ according to the equilibrium constant (Keq):
Keq (Cr) = [ATP] ´[Cr]/[ADP] ´[PCr] ´[H+]
Keq (cyCr) = [ATP] ´[cyCr]/[ADP] ´[PcyCr] ´[H+]
In our study, the increase in Cr exceeds the increase in PCr,
possibly leading to a decrease in ADP concentration, which will
increase the phosphorylation potential and decrease the rate of
oxidative metabolism. In contrast, the acidification of tumours
may lower the ADP concentration (provided that all other concen-
trations are unchanged) and increase the oxidative phosphorylation
rate. Thus, changes in oxidative phosphorylation/glycolysis rate
may not be reflected in the MRS-detectable energetic ratios
PCr+PcyCr/NTP and NTP/Pi. Unfortunately, calculation of the
phosphorylation potential was not possible in these experiments.
The apparent increase in PCr+PcyCr/NTP ratio does not neces-
sarily translate into an improved energetic state, and the tumours
may actually be energy deprived as PcyCr is 30-fold more stable
than PCr, and its turnover is 160 times less efficient in vitro
(LoPresti et al, 1989). Consequently, the NTP/Pi ratio may be
better than the PCr+PcyCr/NTP ratio as an indicator of the ener-
getic state of the tumour in the absence of ADP concentrations and
calculations of phosphorylation potential. NTP/Pi was not signifi-
cantly affected in any of the experimental groups except for the
group fed 5% Cr, in which its increase was the result of lower Pi
concentrations (Table 1). Growth inhibition does not seem to be
caused by energy deficiency measured by MRS as NTP/Pi or
PCr+PcyCr/Pi, but other energetic effects not reflected in these
ratios cannot be excluded.
It is evident from the present results that Cr and cyCr had a
direct cytostatic effect on tumour cells, as previously demonstrated
in vitro (Schiffenbauer et al, 1996). Growth inhibition was associ-
ated with tumour acidification, starting from relatively alkaline pH
values in controls, characteristic of most untreated tumours
(Griffith, 1991). The effect of Cr and cyCr may be mediated by
lactate accumulation secondary to inhibition of oxidative phospho-
rylation. However, the low pH values were not accompanied by
high intratumoral lactate concentrations. The observation that
lactate concentrations were not raised further supports the concept
Table 2Pseudo-first-order rate constants (k) and reaction velocity (v) of
phosphate transfer from PCr to NTP in the four experimental groups
k(s–1) v (mmol coil–1 min–1)
Control 0.18 ±0.03 1.04 ±0.18
Cr 2.5% 0.15 ±0.02 0.75 ±0.2
Cr 5% 0.12 ±0.02 0.92 ±0.14
cyCr 0.025% 0.31 ±0.04a –
cyCr 0.1% 0a 0a
aP< 0.05 vs control.
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Figure 5Tissue water content in LS174T tumours (grey) and liver tissue
(white) of nude mice. Experimental groups were compared with controls by a
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that energy metabolism was not impaired. In parallel, high plasma
glucose levels indicate ample substrate delivery to the tumour, and
the stable NTP/Pi ratio suggests that the tumours were adequately
perfused. This index was shown to be a sensitive detector of
changes in blood flow in ex vivo mammary adenocarcinoma
preparations; in this tumour NTP/Pi was most sensitive to changes
in carbon substrate supply and less to oxygen delivery (Eskey et al,
1993). The present experiments address directly only chronic
effects of Cr and cyCr administration, via an oral route, in
tumour-bearing mice. Our findings corroborate the results of
Schiffenbauer et al (1996), who found no changes in NTP levels
and a gradual increase in PcyCr during 12–20 h of acute cyCr
administration in vitro.
The undetectable phosphate transfer rate between PCr and g-
NTP in the 0.1% cyCr group indicated that this tumour contained
almost exclusively PcyCr. The turnover of phosphate between
PcyCr and NTP is slower than the nuclear magnetic resonance
(NMR)-detectable time scale for saturation transfer. It follows,
from the increased rate of saturation transfer in the 0.025% cyCr
group, that, whenever present, PCr was the donor/acceptor of
high-energy phosphate. Although the kinetic properties of PcyCr
may induce changes in intracellular environment, such as lowering
ADP levels, its chronic administration did not decrease NTP/Pi or
total NTP concentration (Table 1). Chronic cyCr administration
allowed the replenishment of Pi, as there were no signs of a
decrease in Pi concentration in any of the cyCr-treated groups.
Growth inhibition by Cr and cyCr
In the present experiments, we found a close relationship between
growth inhibition and concentration of Cr and cyCr (Figure 4 and
Table 1) that was consistent with a direct toxic effect of these CK
substrates. In contrast to the total substrate concentrations, there
was a very poor correlation between growth inhibition and the
steady-state intratumoral concentration of PCr and PcyCr (Figure
4). Thus, the concentration of substrate seems to be more impor-
tant than the concentration of phosphorylated products for the
growth-inhibitory effect of both compounds. Intracellular ‘trap-
ping’ of Cr and cyCr due to phosphorylation may well occur and
would explain the increased effect of cyCr in tumours with high
CK activity and after transfection of cancer cells with the CK gene
(Lillie et al, 1993). This possibility is further supported by the fact
that there seems to be a steep dose–response curve in the dose
range applied in the present experiments (Figure 1) and in experi-
ments by other investigators (Lillie et al, 1993; Miller et al, 1993).
It is noteworthy that the total tumour concentrations of cyCr and
Cr were comparable (6.2 ± 0.1 in the 0.1% cyCr group compared
with 10.3 ± 2.4 in the 5% Cr group), despite a dietary Cr/cyCr ratio
of 50:1 (Table 1). These numbers indicate a preferential uptake of
cyCr into the tumour tissue. The role of a specific sodium-depen-
dent transporter of Cr and cyCr (Guimbal et al, 1993; Sora et al,
1994) remains to be determined. This transport molecule may have
a higher affinity for cyCr than Cr. Estimates indicate that 48–67%
of Cr transport from interstitial fluid to the intracellular space is
sodium dependent at [Na+] = 155 mM and [cyCr] = 5 mM
(Schiffenbauer et al, 1996). At cyCr concentrations much greater
than the estimated Km value of 0.54 mM, passive diffusion becomes
more important. As cyCr is found, in this and other (Schiffenbauer
et al, 1996) studies, to be active at a concentration of 5 mM, the co-
transport of sodium and Cr/cyCr may be involved in the mecha-
nism of action of these compounds. The in vivo growth-inhibitory
effect was achieved at an oral dose of cyCr 5–10 times lower than
in the studies by Lillie et al (1993) and Miller et al (1993), whereas
the effective i.p. dose in this study (10 mg daily) was comparable to
the i.p. dose used by others (Teicher et al, 1995; Schimmel et al,
1996). However, the intratumoral substrate concentration of
5.9 mM reached in the 0.1% cyCr group (Table 1) was very close to
the reported in vitro growth-inhibitory levels of 7–20 mM (Martin
et al, 1994a). The fact that growth inhibition was observed at
similar concentrations in vitro and in vivo demonstrates that the
effect of cyCr on these tumours are not caused by collapse of
stromal components, e.g. tumour vasculature.
Involvement of CK in growth
Schiffenbauer et al (1996) examined two different cell lines for
cyCr content; the cyCr-sensitive rat glioma cell line C6 had a CK
activity of 0.16 unit mg–1 and a dramatic increase in intracellular
PcyCr content during cyCr perfusion, whereas the CK activity of
the less sensitive ovarian carcinoma line OC238 was tenfold lower
and did not seem to accumulate either PcyCr or cyCr. These obser-
vations may be explained by slower phosphorylation in the OC238
cells (as a result of the lower CK activity), leading to a slower
accumulation of the total amount of cyCr in these cells.
The CK activity of 2.1 units mg–1 is one order of magnitude
higher than that of the tumour line with the highest activity in the
study by Schiffenbauer et al (1996), and exactly the same as the
activity previously reported for the colon adenocarcinoma cell line
Caco-2 (Lillie et al, 1993). The relatively high CK activity in
LS174T may explain the very high sensitivity of these tumours to
Cr and cyCr at very low doses. On the other hand, the CK activity
will only influence the phosphorylation rate and not the intracel-
lular concentration of PCr and PcyCr, provided that the system
is in equilibrium. Thus, once the steady-state concentration of
PCr/PcyCr is reached, the CK activity of the tumour cells may be
less important than the given dose or the plasma concentration of
substrate. It is unknown whether the Cr transporter is expressed in
parallel or is independent of CK.
A recent study has shown that subcellular localization of the
isoenzymes may be of importance for hepatocyte regeneration, as
liver regeneration was impaired in transgenic mice with livers
expressing CK-mit fed Cr and in mice with livers expressing CK-
B fed cyCr (Askenasy and Koretsky, 1997). CK-B is the most
abundant isoform in most tumours (DeLuca et al, 1981; Lillie et al,
1993) and fetal tissues (Hall and DeLuca, 1976). In LS174T, only
cytosolic isoenzymes of CK were detected with an expression of
»90% BB and »10% MB. The association of CK-B with growth,
and the increased sensitivity of growing tissues containing this
isoenzyme to cyCr, suggests that it may be worthwhile to investi-
gate the isoenzyme distribution of tumours for two purposes: (1) to
optimize the anti-tumour effect of Cr and cyCr and (2) to elucidate
the interaction between enzymes and substrates in the mechanism
of action of Cr and cyCr. The isozyme distribution in LS174T
tumours (»90% BB) is very close to the distribution in colon
washings from normal subjects (Bereznitsky et al, 1982).
Water accumulation
Neither Cr nor cyCr induced significant water accumulation in the
tumour tissue in spite of significant growth inhibition (Figure 5).
In contrast, both treatment modalities increased the total liver
water content significantly, thus corroborating previous studies ofwater accumulation in liver tissue after Cr and cyCr treatment
(Askenasy and Koretsky, 1997). However, in that study, the
induced hepatic oedema could not explain the inhibitory effect on
liver growth. Correspondingly, we did not find evidence that the
tumour growth-inhibitory effect is attributable to intratumoral
water accumulation in vivo, although this mechanism has been
suggested to be of importance for inhibition of in vitro tumour cell
proliferation (Schiffenbauer et al, 1995). Similarly, the induction
of oedema in itself could not explain the growth-inhibitory effect
of cyCr on C6 or OC238 cells (Schiffenbauer et al, 1996).
Systemic effects
Severe fasting and weight loss has previously been shown to
inhibit tumour growth (Giovanella et al, 1982), but in the present
experiments the lack of correlation between weight loss and
growth inhibition indicated that weight loss was not the direct
cause of growth inhibition. This is further corroborated by the
observation that i.p. injections of cyCr did not induce weight loss,
but did inhibit tumour growth (Figure 2), at a dose (10 mg i.p.
daily) directly comparable to the amount of cyCr ingested by the
mice fed 0.1% cyCr. Finally, because both colon tumours
(Bartholomew and Schutt, 1971) and cyCr feeding cause mild
hypoglycaemia (unpublished results), plasma glucose levels were
measured. In the absence of significant differences in the experi-
mental groups, growth inhibition cannot be attributed to the non-
specific effects of starvation.
In this study, Cr and cyCr for feeding experiments were mixed in a
viscous liquid diet instead of dry food. In previous experiments
performed in our lab, we observed that the mice were able to
avoid the cyCr crystals when mixed with powdered dry food.
Consequently, the effective dose may be smaller than was assumed in
the previous experiments by Lillie et al (1993) and Miller et al (1993).
Also, the mouse strain may be of importance – nude mice seem to
tolerate less cyCr than immunosufficient mice and there might be a
difference in tolerance between different strains of nude mice.
It is possible that the effect of Cr and/or cyCr is mediated by
acidification of the tumour tissue, but the exact mechanism of
action of these compounds remains unknown. Further studies are
warranted to elucidate the role of CK isozymes on the anti-tumour
effect and to optimize treatment schedules for these drugs alone or
combined with synergistically acting chemotherapeutic agents
(Teicher et al, 1995).
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